Compare VENUS REMEDIES with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES STRIDES PHARMA SCIENCE VENUS REMEDIES/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x -15.7 44.4 - View Chart
P/BV x 1.1 2.1 50.7% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 VENUS REMEDIES   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
VENUS REMEDIES/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs1261,147 11.0%   
Low Rs61642 9.5%   
Sales per share (Unadj.) Rs301.8317.2 95.1%  
Earnings per share (Unadj.) Rs-24.97.8 -317.0%  
Cash flow per share (Unadj.) Rs2.525.1 10.2%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs293.3274.3 106.9%  
Shares outstanding (eoy) m12.3489.50 13.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.8 11.0%   
Avg P/E ratio x-3.8114.0 -3.3%  
P/CF ratio (eoy) x36.735.7 102.9%  
Price / Book Value ratio x0.33.3 9.8%  
Dividend payout %025.5 0.0%   
Avg Mkt Cap Rs m1,15480,058 1.4%   
No. of employees `0000.92.5 36.9%   
Total wages/salary Rs m3934,341 9.1%   
Avg. sales/employee Rs Th4,026.111,325.8 35.5%   
Avg. wages/employee Rs Th425.01,731.4 24.5%   
Avg. net profit/employee Rs Th-331.8280.1 -118.5%   
INCOME DATA
Net Sales Rs m3,72428,394 13.1%  
Other income Rs m23941 2.4%   
Total revenues Rs m3,74729,334 12.8%   
Gross profit Rs m3953,965 10.0%  
Depreciation Rs m3381,540 22.0%   
Interest Rs m3541,962 18.1%   
Profit before tax Rs m-2751,403 -19.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m3297 32.5%   
Profit after tax Rs m-307702 -43.7%  
Gross profit margin %10.614.0 75.9%  
Effective tax rate %-11.56.9 -165.5%   
Net profit margin %-8.22.5 -333.3%  
BALANCE SHEET DATA
Current assets Rs m2,63824,836 10.6%   
Current liabilities Rs m2,30518,993 12.1%   
Net working cap to sales %8.920.6 43.5%  
Current ratio x1.11.3 87.5%  
Inventory Days Days13571 190.8%  
Debtors Days Days46113 40.9%  
Net fixed assets Rs m4,87134,289 14.2%   
Share capital Rs m123895 13.8%   
"Free" reserves Rs m3,49623,651 14.8%   
Net worth Rs m3,61924,546 14.7%   
Long term debt Rs m1,37415,513 8.9%   
Total assets Rs m7,50965,437 11.5%  
Interest coverage x0.21.7 13.0%   
Debt to equity ratio x0.40.6 60.1%  
Sales to assets ratio x0.50.4 114.3%   
Return on assets %0.64.1 15.5%  
Return on equity %-8.52.9 -296.5%  
Return on capital %1.66.9 22.9%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m015,697 0.0%   
Fx outflow Rs m517735 70.2%   
Net fx Rs m-51714,962 -3.5%   
CASH FLOW
From Operations Rs m5141,871 27.5%  
From Investments Rs m-1235,826 -2.1%  
From Financial Activity Rs m-387-10,157 3.8%  
Net Cashflow Rs m4-2,615 -0.2%  

Share Holding

Indian Promoters % 32.9 27.7 118.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 37.8 0.5%  
FIIs % 0.6 8.6 6.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 25.9 256.4%  
Shareholders   20,121 56,241 35.8%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   PANACEA BIOTECH  DIVIS LABORATORIES  FULFORD INDIA  NATCO PHARMA  ELDER PHARMA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

RBI's Relief Measures Amid Covid, 5G Trials by Mobile Operators, and Buzzing Stocks Today(Pre-Open)

Indian share markets witnessed positive trading activity throughout the day yesterday and ended higher.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider(Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


May 5, 2021 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS